Hearing News Watch

MINNEAPOLIS, MINNESOTA – Amplifon, the parent company of U.S. brands Miracle-Ear and Amplifon Hearing Health Care (AHHC), is organizing initiatives worldwide in celebration of World Hearing Day on March 3. The theme for this year, set by the World Health Organization (WHO), focuses on changing mindsets regarding hearing care: recognizing the importance of hearing health, protecting oneself from noise exposure,

FARMINGTON HILLS, MICHIGAN – Members of the International Hearing Society (IHS) are preparing to celebrate World Hearing Day on March 3, 2025, to raise awareness about hearing healthcare and address the stigma surrounding hearing loss and the use of hearing aids. According to the World Health Organization (WHO), by 2030, over 500 million people are expected to experience disabling hearing

BLUFFDALE, UTAH — Listen Technologies Corporation, a leading provider of advanced wireless listening solutions for 26 years, has announced the appointment of David Serpa as the organization’s new financial controller. In this role, Serpa will be responsible for managing accounting records, ensuring compliance with regulations, analyzing financial data, and overseeing accounting operations. He will report to Maile Keone, president and

EDEN PRAIRIE, MINNESOTA – Starkey has announce the appointment of Luke Hellier as its new Government Affairs Director. In this newly created role, Hellier will enhance Starkey’s advocacy efforts, working to advance policies that improve patient access to hearing healthcare while ensuring hearing professionals remain at the center of the process. With more than a decade of experience in public

STAFA, SWITZERLAND – Phonak has successfully launched the Hear My Life Ambassador Relay, beginning with an engaging two-day event featuring World Cup skier Robin Gillon and Olympic sprint kayaker Aaron Small on February 20-21, 2025. Designed to connect Phonak’s brand ambassadors across sports, music, and beyond, the relay highlights individuals who break barriers and inspire people with hearing loss. Both

TARRYTOWN, NEW YORK – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data from the Phase 1/2 CHORD trial evaluating the investigational gene therapy DB-OTO in children with profound genetic hearing loss caused by otoferlin (OTOF) gene variants. The latest findings, presented at the Association for Research in Otolaryngology’s (ARO) 48th Annual MidWinter Meeting, include 72-week results showing speech and

LOS ANGELES, CALIFORNIA — The brain may play a role in helping the ear regulate its sensitivity to sound and compensate for hearing loss by sending a signal to the cochlea, according to a study that was just published in the Journal of Neuroscience. The discovery could help researchers develop treatments for tough-to-treat hearing disorders such as hyperacusis, where everyday

Registration is now open for exhibitors at the 69th International Congress of Hearing Aid Acousticians (EUHA), taking place from 22–24 October 2025 in Nuremberg. As of 12 February 2025, companies can secure exhibition space at the event via www.ausstellung-euha.org/en. On the first day of registration alone, more than 20 companies confirmed their participation. New Exhibition Hall & Expanded EUHA Live

MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company specializing in novel therapies for hearing loss, announced that the Data Monitoring Committee (DMC) has recommended the continuation of the Audiogene Phase 1/2 clinical trial of SENS-501, a gene therapy program aimed at treating congenital deafness caused by OTOF (otoferlin) gene mutations. The DMC’s recommendation follows a review of

SEATTLE, WASHINGTON – Sound Pharmaceuticals will present new preclinical and clinical data on SPI-1005 at the upcoming Association for Research in Otolaryngology (ARO) MidWinter Meeting in Orlando, FL. The company will deliver four presentations highlighting advancements in hearing loss and tinnitus research, including findings on ebselen’s potential to reverse noise-induced tinnitus and SPI-1005’s efficacy in Meniere’s disease treatment. Presentations at